Clinical and Regulatory Concerns of Biosimilars: A Review of Literature
Although biosimilars have been part of clinical practice for more than a decade, healthcare professionals (HCPs) do not fully accept them. This is because of the perception that biosimilars may not be like their originators in terms of quality, safety, and efficacy. This study aims to evaluate the c...
Main Authors: | Vesa Halimi, Armond Daci, Katerina Ancevska Netkovska, Ljubica Suturkova, Zaheer-Ud-Din Babar, Aleksandra Grozdanova |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | International Journal of Environmental Research and Public Health |
Subjects: | |
Online Access: | https://www.mdpi.com/1660-4601/17/16/5800 |
Similar Items
-
Authorisation of Non-Innovator Biotherapeutic (Biosimilar) Products in the USA
by: A. A. Soldatov, et al.
Published: (2019-03-01) -
REGULATORY CONSIDERATIONS OF BIOSIMILARS AND CLINICAL DILEMA OF THEIR USE
by: Sonja Genadieva Stavrik, et al.
Published: (2017-04-01) -
An Update Review of Biosimilars of Adalimumab in Psoriasis – Bioequivalence and Interchangeability
by: Zhou X, et al.
Published: (2021-07-01) -
The biosimilars journey: current status and ongoing challenges
by: Igor Age Kos, et al.
Published: (2018-10-01) -
Biosimilars, the journey has begun
by: Alba Martos-Rosa, et al.
Published: (2015-01-01)